You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Prospects for control of emerging infectious diseases with plasmid DNA vaccines
|
|---|---|
| Published in |
Journal of Immune Based Therapies and Vaccines, September 2009
|
| DOI | 10.1186/1476-8518-7-3 |
| Pubmed ID | |
| Authors |
Ronald B Moss |
| Abstract |
Experiments almost 20 years ago demonstrated that injections of a sequence of DNA encoding part of a pathogen could stimulate immunity. It was soon realized that "DNA vaccination" had numerous potential advantages over conventional vaccine approaches including inherent safety and a more rapid production time. These and other attributes make DNA vaccines ideal for development against emerging pathogens. Recent advances in optimizing various aspects of DNA vaccination have accelerated this approach from concept to reality in contemporary human trials. Although not yet licensed for human use, several DNA vaccines have now been approved for animal health indications. The rapid manufacturing capabilities of DNA vaccines may be particularly important for emerging infectious diseases including the current novel H1N1 Influenza A pandemic, where pre-existing immunity is limited. Because of recent advances in DNA vaccination, this approach has the potential to be a powerful new weapon in protecting against emerging and potentially pandemic human pathogens. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 71 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 23% |
| Student > Bachelor | 12 | 17% |
| Student > Ph. D. Student | 7 | 10% |
| Student > Master | 7 | 10% |
| Student > Doctoral Student | 5 | 7% |
| Other | 13 | 18% |
| Unknown | 11 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 22 | 31% |
| Biochemistry, Genetics and Molecular Biology | 10 | 14% |
| Medicine and Dentistry | 7 | 10% |
| Immunology and Microbiology | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Other | 9 | 13% |
| Unknown | 14 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2022.
All research outputs
#4,836,164
of 25,374,917 outputs
Outputs from Journal of Immune Based Therapies and Vaccines
#10
of 32 outputs
Outputs of similar age
#18,004
of 103,202 outputs
Outputs of similar age from Journal of Immune Based Therapies and Vaccines
#1
of 2 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.1. This one scored the same or higher as 22 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 103,202 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them